Condition

Hemophilia clinical trials

Q: Are hemophilia clinical trials free to join?

Taking part is generally free to you, and many trials cover study-related visits, tests, and the study drug at no cost. What's covered varies by study, and the study team confirms the details.

Q: Do you get paid for hemophilia clinical trials?

Some studies offer compensation for your time and travel; the amount varies by study and some offer none. Any compensation is set by the study.

Q: How do I know if I qualify for a hemophilia trial?

Each study sets its own eligibility criteria, such as age, health history, and current medications. You share a few details and the study team reviews and confirms whether you're a fit.

Q: Is BridgeMD the study sponsor?

No. BridgeMD is a free tool that helps you find recruiting trials and apply online. Trial information comes from ClinicalTrials.gov, and the study team decides eligibility.

87 studies mentioning hemophilia are recruiting now. Open one to see what it involves.

Recruiting hemophilia studies right now

Study details and eligibility ClinicalTrials.gov record

Also recruiting in Europe

Trials that mention Hemophilia and that the EU Clinical Trials Information System (CTIS) lists as recruiting. Each card names the countries where recruitment is open. Open a study to see its details and a link to the European registry.

B7841008 - AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS Recruiting in Austria, Czechia, Denmark, Italy, Slovakia, Spain EU CTIS Therapeutic confirmatory (Phase III) Study details

A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B Recruiting in Bulgaria, Spain EU CTIS Human Pharmacology (Phase I)- Other Study details

Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies. Recruiting in Bulgaria EU CTIS Therapeutic confirmatory (Phase III) Study details

A two-part open-label Study of REGV131-LNP1265, A crispr/cas9-based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B Recruiting in France, Germany, Italy, Spain EU CTIS Phase I and Phase II (Integrated)- First administration to humans Study details

An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX Recruiting in Belgium, Poland, Spain EU CTIS Therapeutic confirmatory (Phase III) Study details

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial Recruiting in Germany EU CTIS Therapeutic confirmatory (Phase III) Study details